STOCK TITAN
  1. Home
  2. Sec-filings
  3. LPCN
  4. [Form 3] Lipocine Inc. Initial Statement of Beneficial Ownership

Lipocine Inc. (LPCN) director Grissinger files initial ownership statement

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Lipocine Inc. filed an initial beneficial ownership report for Michael Grissinger, who is identified as a director but not an officer or ten percent owner. The filing reports no equity holdings or insider transactions for him at this time.

Positive

  • None.

Negative

  • None.
Reported buy transactions 0 Number of buy transactions reported in this initial insider filing
Reported sell transactions 0 Number of sell transactions reported in this initial insider filing
Holding entries 0 Total holding entries shown for Michael Grissinger
beneficial ownership regulatory
"Initial beneficial ownership report filed for director Michael Grissinger"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
reporting person regulatory
"The reporting person is identified as a director of Lipocine Inc."
ten percent owner regulatory
"He is indicated as not a ten percent owner in the insider data"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →

FAQ

What does the Lipocine (LPCN) insider filing for Michael Grissinger show?
It shows an initial beneficial ownership report for director Michael Grissinger at Lipocine Inc. He is listed as a director, not an officer or ten percent owner, and the filing reports no share holdings or insider stock transactions for him.

Is Michael Grissinger a director, officer, or ten percent owner at Lipocine (LPCN)?
He is reported as a director of Lipocine Inc. The filing indicates he is not an officer and not a ten percent owner. This clarifies his governance role without indicating any controlling or large ownership stake in the company.

Does the Lipocine (LPCN) filing report any stock transactions by Michael Grissinger?
No. The insider data show no reported transactions for Michael Grissinger. Transaction counts for buys, sells, exercises, gifts, and restructurings are all zero, indicating this filing is purely an initial ownership status report without trading activity.

Does the Lipocine (LPCN) report list any share holdings for Michael Grissinger?
No share holdings are listed for Michael Grissinger. The summary data include zero holding entries and no derivative positions, so this initial filing only establishes his status as a director without disclosing any current equity position.

Why was an initial beneficial ownership statement filed for Lipocine (LPCN)?
An initial beneficial ownership statement is required when someone becomes an insider, such as a director. This filing records Michael Grissinger’s insider status at Lipocine Inc., confirming his role and that there are no reported holdings or trades at this point.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Grissinger Michael
(Last)(First)(Middle)
675 ARAPEEN DRIVE,
SUITE 202
(Street)
SALT LAKE CITY UTAH 84108
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2026		3. Issuer Name and Ticker or Trading Symbol
Lipocine Inc. [ LPCN ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
No securities are beneficially owned.
/s/ Michael Grissinger08/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR